MedPath

Therapeutic Hypothermia After Cardiac Arrest in Non Shockable Rhythm

Not Applicable
Completed
Conditions
Cardiac Arrest
Interventions
Procedure: Targeted controlled temperature between 36.5 and 37.5°C
Procedure: Targeted controlled temperature between 32.5 and 33.5°C
Registration Number
NCT01994772
Lead Sponsor
Centre Hospitalier Departemental Vendee
Brief Summary

Cardiac arrest is at present a major cause of mortality as well as a cause of disability for the surviving victims.In Europe, every year counts as 300,000 cardiac arrests responsible for 250,000 deaths. Thus, less than 20 % of patients discharged home with impaired quality of life associated with symptoms of tiredness, stress, anxiety. The prognosis is related to the initial cardiac rhythm present during the initiation of resuscitation. Recent progress in the improvement of mortality and neurological outcome has been achieved over the last decade thanks to the systematic implementation of a period of targeted temperature control between 32 and 34 ° C in patients who benefited from the realization of at least one electrical external shock.

There are theoretical and clinical arguments to think that achieving the same way a period of targeted temperature control between 32 and 34 ° C in patients treated for cardiac arrest with a non- shockable rhythm on arrival can also benefit from this procedure. However other arguments are against this hypothesis including an increase in the risk of infection , worsening of the patient's hemodynamic status with no benefit to him. To answer this question, we conduce a randomized multicenter study testing the potential improvement of neurological outcome through this procedure targeted temperature control between 32.5 and 33.5 ° C in these patients.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
584
Inclusion Criteria
  • Cardiac arrest in non shockable rhythm
  • Glasgow score ≤ 8
Exclusion Criteria
  • No flow > 10 min
  • Low flow > 60 min
  • Major hemodynamic instability
  • Delay between cardiac arrest and inclusion > 300 min
  • Cirrhosis Child C
  • Age < 18 years
  • Pregnant women
  • Patient with no liberty
  • Lack of informed consent
  • Prior inclusion in a research protocol involving cardiac arrest with draw, and whose primary endpoint focuses on the evaluation of a neurological score Day 90

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Targeted controlled temperature between 36.5 and 37.5°CTargeted controlled temperature between 36.5 and 37.5°CPatients will be placed in targeted temperature control between 36.5 and 37.5 ° C for 48 hours.
Targeted controlled temperature between 32.5 and 33.5°CTargeted controlled temperature between 32.5 and 33.5°CPatients will be placed in targeted temperature control between 32.5 and 33.5 ° C for 24 hours and then slowly rewarmed for targeted temperature control between 36.5 and 37.5 ° C for 24 hours.
Targeted controlled temperature between 32.5 and 33.5°CTargeted controlled temperature between 36.5 and 37.5°CPatients will be placed in targeted temperature control between 32.5 and 33.5 ° C for 24 hours and then slowly rewarmed for targeted temperature control between 36.5 and 37.5 ° C for 24 hours.
Primary Outcome Measures
NameTimeMethod
Neurological outcome assessed with Cerebral Performance Category scaleDay 90
Secondary Outcome Measures
NameTimeMethod
Intensive Care Unit MortalityDischarge from Intensive Care Unit, an expected average of 7 days

Participants will be followed for the duration of Intensive Care Unit stay, an expected average of 7 days.

Hospital MortalityDischarge from hospital, an expected average of 2 weeks

Participants will be followed for the duration of hospital stay, an expected average of 2 weeks

Mortality at day 90Day 90
Quality of life ScoreDay 90

Quality of life at day 90 will be assessed by 36-Items Short Form for Health Survey telephonic interview

Life autonomyDay 90

Life autonomy will be assessed by Index Activity of Daily Living, modified Barthel index, and by two normative question about life autonomy

Neurocognitive evaluationDay 90

Neurocognitive status will be assessed by telephonic validated version of Mini Mental State Examination

Post traumatic stress disorders symptomsDay 90

Post traumatic stress disorders symptoms will be assessed by Impact Event Scale Revised

Intensive Care Unit length of stayDischarge from Intensive Care Unit, an expected average of 7 days

Participants will be followed for the duration of Intensive Care Unit stay, an expected average of 7 days

Hospital length of stayDischarge from hospital, an expected average of 2 weeks

Participants will be followed for the duration of hospital stay, an expected average of 2 weeks.

Mechanical ventilation durationTime from extubation, an expected average of 4 days

Participants will be followed for the duration of mechanical ventilation, an expected average of 4 days

Severe hemorrhageIntensive care unit length of stay, an expected average of 7 days

Severe hemorrhage is define by transfusion of 1 or more blood product requirement and/or intracranial hemorrhage. Participants will be followed for the duration of Intensive care unit stay, an expected average of 7 days.

Nosocomial Bloodstream infectionIntensive care unit length of stay, an expected average of 7 days

Participants will be followed for the duration of Intensive care unit stay, an expected average of 7 days.

Early onset pneumonia2 days
Ventilated Associated PneumoniaDuration of mechanical ventilation, an expected average of 4 days

Participants will be followed for the duration of mechanical ventilation, an expected average of 4 days

Central Veinous Catheter infectionIntensive care unit length of stay, an expected average of 7 days

Participants will be followed for the duration of Intensive care unit stay, an expected average of 7 days.

Total dose of inotropic drugs48 hours

Total dose of different inotropic drugs (Epinephrine, Norepinephrine, Dobutamine) will be compare between 2 groups during targetted controlled temperature management period.

Extra renal support requirementIntensive care unit length of stay, an expected 7 days

Participants will be followed for the duration of Intensive care unit stay, an expected average of 7 days

Acute pulmonary oedema by left ventricular failureIntensive care length of stay, an expected 7 days

Participants will be followed for the duration of Intensive care unit stay, an expected average of 7 days.

SeizureIntensive care length of stay, an expected 7 days

Participants will be followed for the duration of Intensive care unit stay, an expected average of 7 days

Severe arrythmiaIntensive care unit length of stay, an expected 7 days

Severe arrythmia will be define by salvo of ventricular extrasystole, ventricular fibrillation, ventricular tachycardia, need an external shock, need anti-arrhythmic treatment. Participants will be followed for the duration of Intensive Care Unit stay, an expected average of 7 days.

Trial Locations

Locations (4)

Medical Intensive Care Unit

🇫🇷

Tours, France

Medical Surgical Intensive Care Unit

🇫🇷

Versailles, France

CHU Pointe à Pitre

🇬🇵

Pointe-à-Pitre, Guadeloupe

Cochin University Hospital Center

🇫🇷

Paris, France

© Copyright 2025. All Rights Reserved by MedPath